Shopping Cart 0
Cart Subtotal
USD 0

Secondary (Hypogonadotropic) Hypogonadism-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000

Details

Secondary (Hypogonadotropic) Hypogonadism-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism-Pipeline Review, H1 2017, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.

Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary (Hypogonadotropic) Hypogonadism-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism (Male Health).

The pipeline guide reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary (Hypogonadotropic) Hypogonadism-Overview

Secondary (Hypogonadotropic) Hypogonadism-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Secondary (Hypogonadotropic) Hypogonadism-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Secondary (Hypogonadotropic) Hypogonadism-Companies Involved in Therapeutics Development

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

Secondary (Hypogonadotropic) Hypogonadism-Drug Profiles

BGS-649-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corifollitropin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enclomiphene citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IAS-167A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kisspeptin-10-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSS-722-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Secondary (Hypogonadotropic) Hypogonadism-Dormant Projects

Secondary (Hypogonadotropic) Hypogonadism-Discontinued Products

Secondary (Hypogonadotropic) Hypogonadism-Product Development Milestones

Featured News & Press Releases

Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis

Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism

Aug 15, 2016: Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men

Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism

Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company

Jan 04, 2016: Repros Updates Enclomiphene Program

Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene

Oct 29, 2015: Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism

Jun 08, 2015: Repros Announces Date of FDA Advisory Committee Review of NDA

Apr 15, 2015: Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Pipeline by Merck & Co Inc, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Pipeline by Mereo Biopharma Group Plc, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Pipeline by Repros Therapeutics Inc, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Dormant Projects, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Merck & Co Inc, Mereo Biopharma Group Plc, Repros Therapeutics Inc

Company Profile

Company Profile Title

Secondary (Hypogonadotropic) Hypogonadism-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism-Pipeline Review, H1 2017, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.

Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary (Hypogonadotropic) Hypogonadism-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary (Hypogonadotropic) Hypogonadism (Male Health).

The pipeline guide reviews pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Secondary (Hypogonadotropic) Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Secondary (Hypogonadotropic) Hypogonadism (Male Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Secondary (Hypogonadotropic) Hypogonadism-Overview

Secondary (Hypogonadotropic) Hypogonadism-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Secondary (Hypogonadotropic) Hypogonadism-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Secondary (Hypogonadotropic) Hypogonadism-Companies Involved in Therapeutics Development

Merck & Co Inc

Mereo Biopharma Group Plc

Repros Therapeutics Inc

Secondary (Hypogonadotropic) Hypogonadism-Drug Profiles

BGS-649-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corifollitropin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enclomiphene citrate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IAS-167A-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kisspeptin-10-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSS-722-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Secondary (Hypogonadotropic) Hypogonadism-Dormant Projects

Secondary (Hypogonadotropic) Hypogonadism-Discontinued Products

Secondary (Hypogonadotropic) Hypogonadism-Product Development Milestones

Featured News & Press Releases

Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis

Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism

Aug 15, 2016: Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men

Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men

Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism

Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company

Jan 04, 2016: Repros Updates Enclomiphene Program

Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene

Oct 29, 2015: Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism

Jun 08, 2015: Repros Announces Date of FDA Advisory Committee Review of NDA

Apr 15, 2015: Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Pipeline by Merck & Co Inc, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Pipeline by Mereo Biopharma Group Plc, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Pipeline by Repros Therapeutics Inc, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Dormant Projects, H1 2017

Secondary (Hypogonadotropic) Hypogonadism-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Merck & Co Inc, Mereo Biopharma Group Plc, Repros Therapeutics Inc